Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer

被引:13
作者
Baldini, E
Tibaldi, C
Pfanner, E
Ricci, S
Falcone, A
Ceribelli, A
Sarcina, R
Comella, G
Stampino, CG
Conte, PF
机构
[1] ST CHIARA HOSP,DIV MED ONCOL,UO ONCOL MED,I-56100 PISA,ITALY
[2] IST REGINA ELENA,DIV MED ONCOL,I-00161 ROME,ITALY
[3] INST ONCOL,BARI,ITALY
[4] INST CANC RES,DIV MED ONCOL,NAPLES,ITALY
[5] MED DIRECT ROCHE,MILAN,ITALY
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1996年 / 19卷 / 06期
关键词
elderly patients; advanced non-small-cell lung cancer; oral doxifluridine;
D O I
10.1097/00000421-199612000-00013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Elderly patients with advanced non-small-cell lung cancer (NSCLC) are usually excluded from most clinical trials because of the toxicity associated with chemotherapy. About 50% of the new cases of lung cancer occur in patients older than 65 years. Doxifluridine is a fluoropyrimidine derivate which can be administered orally with very low toxicities. This phase II study evaluates the toxicity and activity of a home therapy with oral doxifluridine in elderly advanced NSCLC patients. Thirty-three advanced NSCLC patients. aged 70 years or mon, entered the study; median ECOG performance status was 1 (0-2) and 22 patients (66.6%) had metastatic disease. Doxifluridine was given orally in three divided doses, for a total daily dose of 2,250 mg, for 3 consecutive days every week. The treatment was well tolerated; five patients(15%) experienced a grade 3 diarrhea which required doxifluridine dose reduction to 1.500 mg daily. Thirty-one patients are evaluable for response: four partial responses (12.9%) have been observed (95% confidence limit interval 3.6-29.8%): 17 patients (54.8%) had a stabilization of the disease. This study demonstates that a home therapy with oral doxifluridine in elderly NSCLC patients is feasible and well tolerated and should encourage further studies.
引用
收藏
页码:592 / 594
页数:3
相关论文
共 7 条
[1]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[2]  
ARMSTRONG RD, 1981, CANCER RES, V41, P4891
[3]   TUMOR INHIBITORY EFFECTS OF A NEW FLUOROURACIL DERIVATIVE - 5'-DEOXY-5-FLUOROURIDINE [J].
BOLLAG, W ;
HARTMANN, HR .
EUROPEAN JOURNAL OF CANCER, 1980, 16 (04) :427-432
[4]   ORAL DOXIFLURIDINE IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL-CANCER - A MULTICENTER PHASE-II STUDY [J].
FALCONE, A ;
PFANNER, E ;
RICCI, S ;
BERTUCCELLI, M ;
CIANCI, C ;
CARRAI, M ;
DEMARCO, S ;
CERIBELLI, A ;
BARDUAGNI, M ;
CALABRESI, F ;
COMELLA, G ;
SARCINA, R ;
LORUSSO, V ;
STAMPINO, CG ;
PANDOLFI, A ;
BRUZZI, P ;
CONTE, PF .
ANNALS OF ONCOLOGY, 1994, 5 (08) :760-762
[5]  
JENSEN OM, 1990, EUR J CANCER, V26, P1167
[6]  
SOUPHET PJ, 1993, LANCET, V342, P19
[7]  
WINKELMANN JJ, 1990, B CANCER, V77, P225